Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | GAPDH | P04406 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998090 | 0.89 | PI4KA (0.48) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL6935380 | 0.88 | PI4KA (0.48) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL2228473 | 0.88 | PI4KA (0.39) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL5742060 | 0.87 | PI4KA (0.47) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL9495963 | 0.86 | PI4KA (0.46) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL3488876 | 0.86 | ADORA3 (0.47) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL4884759 | 0.86 | EHMT1 (0.48) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| Niacinamide SCHEMBL8447045 | 0.85 | EGFR (0.47) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL934614 | 0.85 | ADORA3 (0.47) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL7200116 | 0.85 | ADORA3 (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1624 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026107412-A1 | SARCOSPAN MODULATION AND METHODS OF MEAT AND TISSUE CULTURE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2025217007-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2025217015-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2025217008-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND SOS1 INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312344-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250312351-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND SOS1 INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250312343-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| EP-4580628-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND BCL-2 FAMILY INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-12331343-B2 | FAMIN assay methods | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-17 | — | — | US | claimed |
| EP-0675712-A4 | REDUCTION OF HAIR GROWTH EMPLOYING SULFHYDRYL REACTIVE COMPOUNDS. | HANDELMAN JOSEPH H (US) | 1996-11-06 | — | — | EP | claimed |
| WO-1996033703-A2 | S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY | ORIDIGM CORPORATION (US) | 1996-10-31 | — | — | WO | claimed |
| CN-1121356-A | Use of tomato E8-derived promoters to express heterologous genes, E.G. 5-adenosylmethionine hydrolase, in ripening fruit | EPITOPE INC (US) | 1996-04-24 | — | — | CN | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| EP-0675712-A1 | REDUCTION OF HAIR GROWTH EMPLOYING SULFHYDRYL REACTIVE COMPOUNDS | HANDELMAN, Joseph H. (US) | 1995-10-11 | — | — | EP | claimed |
| EP-0555352-A4 | AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES | HEALTH RESEARCH INC (US) | 1994-12-14 | — | — | EP | claimed |
| WO-1994014428-A1 | REDUCTION OF HAIR GROWTH EMPLOYING SULFHYDRYL REACTIVE COMPOUNDS | HANDELMAN, JOSEPH, H. (US) | 1994-07-07 | — | — | WO | claimed |
| US-4948783-A | ORALLY ADMINISTERING ADENOSINE OR DERIVATIVE | KABUSHIKI KAISYA ADVANCE KAIHATSU KENKYUJO (JP) | 1990-08-14 | — | — | US | claimed |
| US-4562149-A | CULTIVATING A MICROORGANISM IN LIQUID CULTURE MEDIUM CONTAINING METHIONINE | NIPPON ZEON CO., LTD. (JP) | 1985-12-31 | — | — | US | claimed |
| US-3962034-A | CULTURE | AJINOMOTO CO., INC. (JA) | 1976-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312351-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND SOS1 INHIBITORS FOR THE TREATMENT OF CANCER | PRMT1, PRMT5, PRMT6 | ADORA3 3358/4885ADORA2A 2256/4885PI4KA 2564/4885 |
| US-20250312343-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | KRAS, PRMT5, NRAS | ADORA3 2918/4885ADORA2A 1842/4885PI4KA 1262/4885 |
| US-20250312344-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER | PRMT5, PRMT1, PRMT6 | ADORA3 1844/4885ADORA2A 955/4885PI4KA 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.